Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
-
Potential game changer: eye implant could drastically reduce injections for blinding disease
Disease control OngoingThis study is testing if a new, long-acting eye implant (EYP-1901) can work as well as standard aflibercept injections for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It aims to see if the implant can maintain or improve vision while reduc…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Eye implant aims to free patients from frequent injections for blinding disease
Disease control OngoingThis study is testing whether a new, long-acting eye implant (EYP-1901) can work as well as the current standard treatment (aflibercept injections) for wet age-related macular degeneration (AMD). It will involve about 400 people who have this eye condition. The main goal is to se…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC